(415) 419-5450

August 28, 2026 Artificial intelligence is no longer simply a futuristic concept in medicine. In retinal care, AI is rapidly becoming a powerful tool for analyzing the enormous amount of information contained within retinal images and helping physicians detect, quantify, and monitor disease with increasing precision. The retina is uniquely suited to artificial intelligence because much of modern retinal medicine is built around sophisticated imaging. Optical coherence tomogra

June 8, 2026 Age-related macular degeneration (AMD) is one of the leading causes of vision loss among older adults. It affects the macula—the central portion of the retina responsible for sharp, detailed vision—and can make everyday activities such as reading, driving, recognizing faces, and using a computer increasingly difficult. While AMD is generally divided into two main forms, dry AMD and wet AMD, understanding the difference between them is important because they behav

August 4, 2023 We are pleased to announce an important advancement in the treatment of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). The U.S. Food and Drug Administration (FDA) approved IZERVAY® (avacincaptad pegol) for the treatment of geographic atrophy secondary to AMD in August 2023, providing retina specialists with an important new treatment option for patients affected by this progressive condition. Geographic atrophy occurs w

February 17, 2023 Apellis Pharmaceuticals, Inc. (Waltham, MA) today announced that the U.S. FDA has approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide. “The approval of SYFOVRE is the most important event in retinal opht

January 28, 2022 Genentech, a member of the Roche Group, today announced that the FDA has approved Vabysmo™ (faricimab-svoa) for the...

September 1, 2019 Anti-VEGF therapy for exudative macular degeneration places a significant treatment burden both upon patients who must...

November 11, 2017 The MUST trial compared the effectiveness of systemic therapy vs. fluocinolone acetonide implant for severe uveitis. ...

May 4, 2016 5-Year Data from the CATT trial has now become available. The study showed that vision gains secondary to bevacizumab or...

November 13, 2015 Protocol S of the DRCR.net study group is a randomized multi-center clinical trial to evaluate noninferiority of...

March 25, 2015 "Diabetes is a serious public health crisis, affecting more patients every year," Edward Cox, MD, MPH, director of the...

December 15, 2014 Based on the phase 3 RISE/RIDE trials, which show meaningful improvements in diabetic retinopathy in Lucentis-treated...

February 2014 The Argus II retinal prosthesis is 3 x 5 mm and surgically implanted onto the surface of the retina, where it acts to...

January 2014 Five patients with LCA2 had improved visual function within a few months after treatment with a single unilateral injection...